In ZOLGENSMA clinical trials, patients were required to have baseline anti-AAV9 antibody titers of ≤ 1:50, measured using an enzyme-linked immunosorbent assay (ELISA). Evidence of prior exposure to AAV9 was uncommon. The safety and efficacy of ZOLGENSMA in patients with anti-AAV9 antibody ...
Note:Quality Control Data:Creation of calibration curve:Expected standard curve was obtained using this product according to the user manual.Assay of control samples:The test results of control samples (high, middle, and low concentration) was located in the expected concentration ranges.It is ...